NASDAQ:ABMD - ABIOMED Stock Price, Price Target & More

ABIOMED trades on the NASDAQ under the ticker symbol "ABMD."

ABIOMED, Inc. (NASDAQ:ABMD) announced its quarterly earnings data on Thursday, May, 3rd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.16. The medical equipment provider had revenue of $174.44 million for the quarter, compared to the consensus estimate of $164.30 million. ABIOMED had a net margin of 18.89% and a return on equity of 17.58%. ABIOMED's quarterly revenue was up 39.9% on a year-over-year basis. During the same quarter last year, the company posted $0.33 earnings per share. View ABIOMED's Earnings History.

ABIOMED is scheduled to release their next quarterly earnings announcement on Thursday, July, 26th 2018. View Earnings Estimates for ABIOMED.

8 brokerages have issued 12 month target prices for ABIOMED's shares. Their predictions range from $280.00 to $480.00. On average, they anticipate ABIOMED's share price to reach $363.1429 in the next year. This suggests that the stock has a possible downside of 14.2%. View Analyst Ratings for ABIOMED.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ABIOMED in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to ABIOMED include Becton Dickinson and (BDX), Stryker (SYK), Boston Scientific (BSX), FRESENIUS SE &/S (FSNUY), Baxter International (BAX), ResMed (RMD), Teleflex (TFX), Dexcom (DXCM), Hill-Rom (HRC), ICU Medical (ICUI), Insulet (PODD), Globus Medical (GMED), Haemonetics (HAE), Penumbra (PEN) and Cantel Medical (CMD).

Media headlines about ABMD stock have trended somewhat positive this week, according to Accern Sentiment. The research group identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. ABIOMED earned a coverage optimism score of 0.11 on Accern's scale. They also gave headlines about the medical equipment provider an impact score of 45.43 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.

ABIOMED's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (4.72%), Fred Alger Management Inc. (0.86%), Scout Investments Inc. (0.76%), Chicago Capital LLC (0.14%), Rhenman & Partners Asset Management AB (0.14%) and Nisa Investment Advisors LLC (0.12%). Company insiders that own ABIOMED stock include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Henri A Termeer, Martin P Sutter, Michael G Howley, Michael R Minogue, Paul Thomas and William J Bolt. View Institutional Ownership Trends for ABIOMED.

ABMD stock was sold by a variety of institutional investors in the last quarter, including Retirement Systems of Alabama, Scout Investments Inc., Dorsey Wright & Associates, Municipal Employees Retirement System of Michigan, Louisiana State Employees Retirement System, Handelsbanken Fonder AB, Chicago Capital LLC and Fred Alger Management Inc.. Company insiders that have sold ABIOMED company stock in the last year include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Martin P Sutter, Michael G Howley, Michael R Minogue, Paul Thomas and William J Bolt. View Insider Buying and Selling for ABIOMED.

ABMD stock was bought by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Rhenman & Partners Asset Management AB, Nisa Investment Advisors LLC, Bank of Montreal Can, Pendal Group Ltd, Gulf International Bank UK Ltd, Fjarde AP Fonden Fourth Swedish National Pension Fund and NN Investment Partners Holdings N.V.. View Insider Buying and Selling for ABIOMED.

Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ABMD stock can currently be purchased for approximately $423.48.

ABIOMED has a market capitalization of $19.27 billion and generates $593.75 million in revenue each year. The medical equipment provider earns $112.17 million in net income (profit) each year or $2.45 on an earnings per share basis. ABIOMED employs 1,143 workers across the globe.

ABIOMED's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at 978-646-1400 or via email at [email protected]